




SCYNEXIS, Inc.
Investor Relations Department
3501 C Tricenter Boulevard
Durham, NC 27713
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: SCYX

Last Trade: 1.71

Trade Time: 4:00 PM ET
Aug 16, 2017

Change: 0.05 
(+3.012%)

Day Range 1.63 - 1.73

52-Week Range 1.52 - 5.51

Volume 163,618

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

SCYNEXIS, Inc. is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.

We are developing our lead product candidate, SCY-078, as a novel and structurally distinct triterpenoid glucan synthase inhibitor. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 15, 2017

["THINK FUNGUS" - SCYNEXIS Recognizes Fungal Disease Awareness Week Sponsored by the Centers for Disease Control and Prevention \(CDC\)](#)

Aug 14, 2017

[SCYNEXIS Presents New Data Supporting Oral SCY-078 for the Clinical Treatment of Vulvovaginal Candidiasis Infections at the 2017 IDSOG Annual Meeting](#)

Aug 8, 2017

[SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update](#)

Aug 7, 2017

[SCYNEXIS to Present at the Canaccord Genuity Growth Conference](#)

Aug 3, 2017

[SCYNEXIS Announces Initiation of Dosing in Phase 2 Study Evaluating Oral SCY-078 in Vulvovaginal Candidiasis](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Apr 26, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Nov 7, 2016

[Quarterly Report \(10-Q\)](#)